tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RARE Stock Latest News

Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
RatingsUltragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
10d ago
RARE
Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
PremiumRatings
Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
11d ago
RARE
Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating
PremiumRatings
Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating
12d ago
RARE
Buy Rating Affirmed for Ultragenyx Pharmaceutical: Promising Phase III Results of DTX401 Gene Therapy
PremiumRatings
Buy Rating Affirmed for Ultragenyx Pharmaceutical: Promising Phase III Results of DTX401 Gene Therapy
12d ago
RARE
Ultragenyx Reports Positive Phase 3 Gene Therapy Results
PremiumCompany Announcements
Ultragenyx Reports Positive Phase 3 Gene Therapy Results
13d ago
8K
RARE
Ultragenyx announces longer-term result from DTX401 AAV gene therapy study
PremiumThe FlyUltragenyx announces longer-term result from DTX401 AAV gene therapy study
13d ago
RARE
Rezolute appoints Karnawat as Chief Commercial Officer
Premium
The Fly
Rezolute appoints Karnawat as Chief Commercial Officer
1M ago
CYTK
RARE
Ultragenyx’s Strategic Progress with DTX401 Gene Therapy Drives Buy Rating Amid Promising Market Potential
Premium
Ratings
Ultragenyx’s Strategic Progress with DTX401 Gene Therapy Drives Buy Rating Amid Promising Market Potential
1M ago
RARE
Ultragenyx Pharmaceutical: Promising Developments and Strategic Advancements Support Buy Rating
PremiumRatings
Ultragenyx Pharmaceutical: Promising Developments and Strategic Advancements Support Buy Rating
1M ago
RARE
Ultragenyx Begins FDA Application for DTX401 Gene Therapy
PremiumCompany Announcements
Ultragenyx Begins FDA Application for DTX401 Gene Therapy
1M ago
8K
RARE
Ultragenyx initiates rolling submission of BLA to U.S. FDA for DTX401
PremiumThe Fly
Ultragenyx initiates rolling submission of BLA to U.S. FDA for DTX401
1M ago
RARE
Ultragenyx Pharmaceutical’s Setrusumab: A Promising Buy with Potential for Significant Fracture Reduction in Osteogenesis Imperfecta
PremiumRatings
Ultragenyx Pharmaceutical’s Setrusumab: A Promising Buy with Potential for Significant Fracture Reduction in Osteogenesis Imperfecta
1M ago
RARE
Ultragenyx price target lowered to $128 from $136 at Canaccord
PremiumThe FlyUltragenyx price target lowered to $128 from $136 at Canaccord
1M ago
RARE
Ultragenyx Pharmaceutical’s Promising Growth and Financial Outlook: Analyst Recommends Buy
Premium
Ratings
Ultragenyx Pharmaceutical’s Promising Growth and Financial Outlook: Analyst Recommends Buy
2M ago
RARE
Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges
Premium
Company Announcements
Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges
2M ago
RARE
Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating
PremiumRatings
Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating
2M ago
RARE
Ultragenyx Reports Growth Amidst Strategic Advancements
PremiumCompany Announcements
Ultragenyx Reports Growth Amidst Strategic Advancements
2M ago
RARE
Ultragenyx reports Q2 EPS ($1.17), consensus ($1.32)
PremiumThe Fly
Ultragenyx reports Q2 EPS ($1.17), consensus ($1.32)
2M ago
RARE
Ultragenyx backs FY25 revenue view $640M-$670M, consensus $649.53M
PremiumThe Fly
Ultragenyx backs FY25 revenue view $640M-$670M, consensus $649.53M
2M ago
RARE
Ultragenyx Pharmaceutical’s Promising Outlook: Buy Rating Affirmed Amidst Aspire Study Progress
PremiumRatingsUltragenyx Pharmaceutical’s Promising Outlook: Buy Rating Affirmed Amidst Aspire Study Progress
2M ago
RARE
RARE Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
RARE Earnings this Week: How Will it Perform?
2M ago
RARE
Ultragenyx Completes Enrollment for GTX-102 Phase 3 Study
Premium
Company Announcements
Ultragenyx Completes Enrollment for GTX-102 Phase 3 Study
2M ago
8K
RARE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >